In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nektar Therapeutics

www.nektar.com

Latest From Nektar Therapeutics

'Pharma Fireworks': Pipeline Catalysts To Watch Out For In Q2

Scrip looks at some the key clinical and regulatory pharma events that will spark attention during the next three months, according to Biomedtracker's latest quarterly outlook report.

Clinical Trials Drug Review

Opioids: FDA Actions May Silence Call For Moratorium On Approvals

Citizen petition seeks review of all marketed opioids; agency is considering whether new opioids should have comparative benefit over existing drugs.

FDA Regulation

Novartis, Zurich University Spin-out Anaveon Tackles IL-2 Challenges With Fresh Funds

Syncona and Novartis Venture Fund have invested CHF35m in Anaveon, which reckons it can overcome the toxicity and half-life limitations of the cytokine interleukin-2 to enhance the body’s immune response to tumors.

Financing ImmunoOncology

Nektar/Bristol Show Promise With Double IO Combo, But Numbers Are Small

Updated data from PIVOT-02 at the ASCO GU meeting suggest a path for accelerated approval of the NKTR-214/Opdivo combination as first-line treatment of patients with PD-L1-negative urothelial cancers.

Clinical Trials Research & Development
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Inhale Therapeutic Systems Inc.
  • Nektar Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Nektar Therapeutics
  • Senior Management
  • Howard W Robin, Pres. & CEO
    Gil M Labrucherie, SVP, CFO
    Stephen K Doberstein, PhD, SVP, R&D and Chief R&D Officer
    Lisa Decker, PhD, VP, Bus. Dev.
  • Contact Info
  • Nektar Therapeutics
    Phone: (415) 482-5300
    455 Mission Bay Blvd. S.
    San Francisco, CA 94158
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register